Quantumzyme Corp. (OTC: QTZM) announced the publication of its latest research in the Journal of Molecular Graphics & Modelling, detailing a fully in silico enzyme engineering approach to design and evaluate biocatalysts before laboratory validation. The study, which appears in the peer-reviewed journal, explores whether enzyme variants can be computationally optimized prior to experimental testing, potentially streamlining the development of sustainable manufacturing processes for pharmaceuticals.
The research applied virtual screening and computational modeling techniques to evaluate transaminase enzyme variants used in the asymmetric synthesis of L-HPE, a chiral intermediate relevant to certain ACE inhibitor drug manufacturing. Rather than relying solely on traditional experimental iteration, the team employed large-scale virtual screening and ranking methodologies to assess enzyme–substrate interactions, catalytic alignment, and structural stability under defined simulation conditions. This approach enabled the identification of enzyme candidates for subsequent experimental consideration.
Naveen Kulkarni, Chief Executive Officer of Quantumzyme Corp., stated, “Publishing this research in the Journal of Molecular Graphics & Modelling represents an important scientific milestone for Quantumzyme. This study contributes to the growing body of evidence supporting computational enzyme engineering as a complementary tool in biocatalyst development.” He added that by evaluating enzyme variants virtually prior to laboratory testing, the company aims to improve research efficiency and better inform downstream validation efforts.
The full paper is available online at ScienceDirect. The publication underscores the expanding role of computational modeling in biocatalysis research, potentially helping to reduce experimental iteration and improve the prioritization of enzyme candidates for laboratory study.
Additionally, Quantumzyme provided an update on its corporate name change and trading symbol request. The company reported that FINRA has received all necessary information to complete its review, and based on current communications, the name change and new trading symbol are expected in the coming days, subject to FINRA's final approval. The company intends to issue a separate announcement upon effectiveness.
Quantumzyme Corp. is a biotransformation company focused on sustainable enzyme-based solutions for pharmaceutical manufacturing. By integrating quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering, the company aims to deliver scalable, cost-effective biocatalysis solutions that improve industrial sustainability.
